Eastgate Acquisitions Corp (ESAQ) designs the “Intel Chip” for Companies Dealing with Diabetes

Nov. 2, 2014 - PRLog -- Eastgate Acquisitions Corp (ESAQ) Anna Gluskin, CEO and Chairman was recently interviewed on IntelRadio news hosted by Ellis Martin where she explained the goal for Eastgate and it current developments. The interview focused on ESAQ’s revolutionary, non-invasive sublingual insulin tablet. During the interview Ms. Gluskin explained how EastGate is expanding on different technologies and diverse techniques that will allow the company to make these kinds of substances more palatable and more durable in the human body.

Currently EastGate is working towards acquiring the licensing rights to develop and manufacture an intraoral insulin formulation. In doing so, the Company uses a combination of some acquisition, with a majority of it is development in-house which has helped to progress the development of ESAQ’s technology and make it a platform. This means that numerous materials (natural, medicinal and synthetic) can be used as ingredients to potentially make it into commercial drugs.

Ms. Gluskin states, “The Company is continuously developing the various methods that are going to allow for different types of molecules to be acceptable for the body. Insulin happens to be one of the most difficult out there because it’s a large molecule. It’s a protein and when this comes into the body in the way of tablets, let’s say, unprotected symptoms we will call it, just insulin by itself, the body recognizes it as a protein, which means that it has to be dissociated and absorbed before it has its medicinal effect,” she continues, “The whole point of it is we need to bring it into the body, of course without needles, where it’s going to be quickly absorbed in the bloodstream and only after that disassociated and absorb this protein. That is the nutshell of what we’re trying to achieve”

Just recently the Company announced that it has signed a licensing agreement with New Jersey based Purine Pharma to produce and distribute EastGate’s line of nutraceuticals under its own private label. Purine will use its established market position to promote the products internationally. Purine supplies a line of over 200 cold, allergy, analgesic, topical and vitamin and supplement products -over-the-counter and prescription based. EastGate is also engaged in studying drug delivery innovations and alternative dosage forms of existing biologically active molecules.

With the onset of the Ebola epidemic throughout the country, the nutraceuticals industry has been the talk of the market. Aside from diabetes remedies, the company also boasts a suite of anti-microbial nutraceuticals that, among other things, help to not only cleans micro-organisms within 30 minutes but also help to act as a second barrier to re-contamination. Though it is not a cure or an anti-viral option, Eastgate’s ability to offer multiple kinds of drugs and drug delivery methods has given the company a leg up in the industry to tackle many of the issues that face North America today.

For more information on Eastgate Acquisitions and other emerging companies in the medical and nutraceuticals industry, sign up for your free report: http://www.investornewssource.com

Disclaimer can be found at : http://www.investornewssource.com